{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:29:10Z","timestamp":1777501750054,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Indonesia Endowment Fund for Education","award":["LPDP No. 20150722083422"],"award-info":[{"award-number":["LPDP No. 20150722083422"]}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11"],"award-info":[{"award-number":["CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWO VIDI, grant 917.13.350"],"award-info":[{"award-number":["NWO VIDI, grant 917.13.350"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWO VENI, grant 016.176.147"],"award-info":[{"award-number":["NWO VENI, grant 016.176.147"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The use of sodium\u2013glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery. Rats received chow containing empagliflozin (EMPA) (30\u00a0mg\/kg\/day) or control chow. Renal function and electrolyte balance were measured in metabolic cages. Histological and molecular markers of kidney injury, parameters of phosphate homeostasis and bone resorption were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>EMPA resulted in a twofold increase in diuresis, without evidence for plasma volume contraction or impediments in renal function in both sham and MI animals. EMPA increased plasma magnesium levels, while the levels of glucose and other major electrolytes were comparable among the groups. Urinary protein excretion was similar in all treatment groups and no histomorphological alterations were identified in the kidney. Accordingly, molecular markers for cellular injury, fibrosis, inflammation and oxidative stress in renal tissue were comparable between groups. EMPA resulted in a slight increase in circulating phosphate and PTH levels without activating FGF23\u2013Klotho axis in the kidney and bone mineral resorption, measured with CTX-1, was not increased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>EMPA exerts profound diuretic effects without compromising renal structure and function or causing significant electrolyte imbalance in a non-diabetic setting. The slight increase in circulating phosphate and PTH after EMPA treatment was not associated with evidence for increased bone mineral resorption suggesting that EMPA does not affect bone health.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10557-020-06954-6","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T05:09:26Z","timestamp":1584421766000},"page":"311-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of Sodium\u2013Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction"],"prefix":"10.1007","volume":"34","author":[{"given":"Salva R.","family":"Yurista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman H. W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"van Goor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Luuk","family":"Hillebrands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz","family":"de Menezes Montenegro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke U.","family":"Oberdorf-Maass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Daan","family":"Westenbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"6954_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"6954_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"6954_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Stephen D. Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"New England Journal of Medicine"},{"key":"6954_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"6954_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6954_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6954_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","volume":"82","author":"KM Thrailkill","year":"2016","unstructured":"Thrailkill KM, Clay Bunn R, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, et al. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice. Bone. 2016;82:101\u20137.","journal-title":"Bone."},{"key":"6954_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2215\/CJN.04530418","volume":"14","author":"MA de Jong","year":"2019","unstructured":"de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, et al. Effects of dapagliflozin on circulating markers of phosphate homeostasis. Clin J Am Soc Nephrol. 2019;14:66\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"key":"6954_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962\u201371.","journal-title":"Kidney Int"},{"key":"6954_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten E, Pavez Giani MG, Hillebrands J, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21:862\u201373.","journal-title":"Eur J Heart Fail"},{"key":"6954_CR11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"6954_CR12","doi-asserted-by":"crossref","unstructured":"McMurray JJ V, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"6954_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","volume":"32","author":"E Flores","year":"2018","unstructured":"Flores E, Santos-Gallego CG, Diaz-Mej\u00eda N, Badimon JJ. Do the SGLT-2 inhibitors offer more than hypoglycemic activity? Cardiovasc Drugs Ther. 2018;32:213\u201322.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6954_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10557-017-6741-2","volume":"31","author":"M Gupte","year":"2017","unstructured":"Gupte M, Umbarkar P, Lal H. Mechanistic insights of empagliflozin-mediated cardiac benefits: nearing the starting line. Cardiovasc Drugs Ther. 2017;31:229\u201332.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6954_CR15","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/eurheartj\/ehv588","volume":"37","author":"DJ van Veldhuisen","year":"2016","unstructured":"van Veldhuisen DJ, Ruilope LM, Maisel AS, Damman K. Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. Eur Heart J. 2016;37:2577\u201385.","journal-title":"Eur Heart J"},{"key":"6954_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola V-P, Mebazaa A, Brunner-La Rocca H-P, Martens P, et al. The use of diuretics in heart failure with congestion\u2014a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137\u201355.","journal-title":"Eur J Heart Fail"},{"key":"6954_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","volume":"36","author":"K Damman","year":"2015","unstructured":"Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36:1437\u201344.","journal-title":"Eur Heart J"},{"key":"6954_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10741-015-9482-y","volume":"20","author":"C Urso","year":"2015","unstructured":"Urso C, Brucculeri S, Caimi G. Acid\u2013base and electrolyte abnormalities in heart failure: pathophysiology and implications. Heart Fail Rev. 2015;20:493\u2013503.","journal-title":"Heart Fail Rev"},{"key":"6954_CR19","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.","journal-title":"PLoS Biol"},{"key":"6954_CR20","doi-asserted-by":"publisher","first-page":"H459","DOI":"10.1152\/ajpheart.00054.2011","volume":"301","author":"M Yin","year":"2011","unstructured":"Yin M, van der Horst ICC, van Melle JP, Qian C, van Gilst WH, Sillj\u00e9 HHW, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H459\u201368.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"6954_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/cvr\/cvw161","volume":"111","author":"HG Booij","year":"2016","unstructured":"Booij HG, Yu H, De Boer RA, van de Kolk CWA, van de Sluis B, Van Deursen JM, et al. Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia\/reperfusion injury but does not influence heart failure development. Cardiovasc Res. 2016;111:217\u201326.","journal-title":"Cardiovasc Res"},{"key":"6954_CR22","doi-asserted-by":"publisher","first-page":"F500","DOI":"10.1152\/ajprenal.00461.2014","volume":"308","author":"YL Frenay A-RS","year":"2015","unstructured":"Frenay A-RS YL, van der Velde AR, Vreeswijk-Baudoin I, L\u00f3pez-Andr\u00e9s N, van Goor H, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Physiol. 2015;308:F500\u20139.","journal-title":"Am J Physiol Physiol"},{"key":"6954_CR23","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","volume":"59","author":"H Tang","year":"2016","unstructured":"Tang H, Zhang X, Zhang J, Li Y, Del Gobbo LC, Zhai S, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia. 2016;59:2546\u201351.","journal-title":"Diabetologia."},{"key":"6954_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2215\/CJN.09750913","volume":"10","author":"J Blaine","year":"2015","unstructured":"Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10:1257\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"6954_CR25","doi-asserted-by":"publisher","first-page":"438S","DOI":"10.1080\/07315724.2011.10719988","volume":"30","author":"J-P Bonjour","year":"2011","unstructured":"Bonjour J-P. Calcium and phosphate: a duet of ions playing for bone health. J Am Coll Nutr. 2011;30:438S\u201348S.","journal-title":"J Am Coll Nutr"},{"key":"6954_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"6954_CR27","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","volume":"33","author":"M Metra","year":"2012","unstructured":"Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012;33:2135\u201342.","journal-title":"Eur Heart J"},{"key":"6954_CR28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1159\/000493657","volume":"43","author":"V Melenovsky","year":"2018","unstructured":"Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, et al. Kidney response to heart failure: proteomic analysis of cardiorenal syndrome. Kidney Blood Press Res. 2018;43:1437\u201350.","journal-title":"Kidney Blood Press Res"},{"key":"6954_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000363705","volume":"127","author":"A Hundae","year":"2014","unstructured":"Hundae A, McCullough PA. Cardiac and renal fibrosis in chronic cardiorenal syndromes. Nephron Clin Pract. 2014;127:106\u201312.","journal-title":"Nephron Clin Pract"},{"key":"6954_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10741-011-9233-7","volume":"17","author":"SJ Sinkeler","year":"2012","unstructured":"Sinkeler SJ, Damman K, van Veldhuisen DJ, Hillege H, Navis G. A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function. Heart Fail Rev. 2012;17:263\u201370.","journal-title":"Heart Fail Rev"},{"key":"6954_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","volume":"30","author":"P Pellicori","year":"2016","unstructured":"Pellicori P, Cleland JGF, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, et al. Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther. 2016;30:599\u2013609.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"27","key":"6954_CR32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Piotr Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"European Heart Journal"},{"key":"6954_CR33","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"GS Francis","year":"1990","unstructured":"Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724\u20139.","journal-title":"Circulation."},{"key":"6954_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10557-018-6843-5","volume":"33","author":"K Oziera\u0144ski","year":"2019","unstructured":"Oziera\u0144ski K, Balsam P, Kap\u0142on-Cie\u015blicka A, Tymi\u0144ska A, Kowalik R, Grabowski M, et al. Comparative analysis of long-term outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology. Cardiovasc Drugs Ther. 2019;33:77\u201386.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6954_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1161\/hc1102.105264","volume":"105","author":"SS Gottlieb","year":"2002","unstructured":"Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348\u201353.","journal-title":"Circulation."},{"key":"6954_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5049\/EBP.2015.13.1.17","volume":"13","author":"SW Oh","year":"2015","unstructured":"Oh SW, Han SY. Loop diuretics in clinical practice. Electrolytes Blood Press. 2015;13:17.","journal-title":"Electrolytes Blood Press"},{"key":"6954_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","volume":"32","author":"J Tamargo","year":"2018","unstructured":"Tamargo J, Caballero R, Delp\u00f3n E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32:99\u2013119.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6954_CR38","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","volume":"33","author":"F Zannad","year":"2012","unstructured":"Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJV, Swedberg K, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782\u201395.","journal-title":"Eur Heart J"},{"key":"6954_CR39","doi-asserted-by":"publisher","unstructured":"Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, et al. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.117.006540.","DOI":"10.1161\/JAHA.117.006540"},{"key":"6954_CR40","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","volume":"136","author":"M Packer","year":"2017","unstructured":"Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation. 2017;136:1548\u201359.","journal-title":"Circulation."},{"key":"6954_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.carrev.2017.06.007","volume":"19","author":"PA McCullough","year":"2018","unstructured":"McCullough PA, Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, et al. Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2. Rev Cardiovasc Med. 2018;19:51\u201363.","journal-title":"Rev Cardiovasc Med"},{"key":"6954_CR42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.31083\/j.rcm.2018.02.907","volume":"19","author":"AY Kluger","year":"2018","unstructured":"Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, et al. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018;19:41\u20139.","journal-title":"Rev Cardiovasc Med"},{"key":"6954_CR43","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","volume":"4","author":"O Iborra-Egea","year":"2019","unstructured":"Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lup\u00f3n J, Packer M, Heymans S, et al. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl Sci. 2019;4:831\u201340.","journal-title":"JACC Basic Transl Sci"},{"key":"6954_CR44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Y Ye","year":"2018","unstructured":"Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates Na+\/H+ exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32:553\u20138.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6954_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78\u201389.","journal-title":"Diab Vasc Dis Res"},{"key":"6954_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"6954_CR47","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333\u20139.","journal-title":"Diabetologia."},{"key":"6954_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479\u201387.","journal-title":"Diabetes Obes Metab"},{"key":"6954_CR49","doi-asserted-by":"publisher","unstructured":"Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction Between the Sodium\u2010Glucose\u2013Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc. 2018;7. https:\/\/doi.org\/10.1161\/JAHA.117.007046.","DOI":"10.1161\/JAHA.117.007046"},{"key":"6954_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.diabet.2016.05.006","volume":"42","author":"AJ Scheen","year":"2016","unstructured":"Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42:224\u201333.","journal-title":"Diabetes Metab"},{"key":"6954_CR51","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) [Internet]. 2016 [cited 2019 Aug 29]. Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm."},{"key":"6954_CR52","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc17-1011","volume":"40","author":"GN Nadkarni","year":"2017","unstructured":"Nadkarni GN, Ferrandino R, Chang A, Surapaneni A, Chauhan K, Poojary P, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40:1479\u201385.","journal-title":"Diabetes Care"},{"key":"6954_CR53","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/dom.13532","volume":"21","author":"A Cahn","year":"2019","unstructured":"Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes Metab. 2019;21:340\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"6954_CR54","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s13300-017-0232-0","volume":"8","author":"RE Gilbert","year":"2017","unstructured":"Gilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials. Diabetes Ther. 2017;8:451\u20138.","journal-title":"Diabetes Ther"},{"key":"6954_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.dsx.2017.08.003","volume":"12","author":"TD Filippatos","year":"2018","unstructured":"Filippatos TD, Tsimihodimos V, Liamis G, Elisaf MS. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab Syndr. 2018;12:59\u201363.","journal-title":"Diabetes Metab Syndr"},{"key":"6954_CR56","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndtplus\/sfr163","volume":"5","author":"W Jahnen-Dechent","year":"2012","unstructured":"Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5:i3\u201314.","journal-title":"Clin Kidney J"},{"key":"6954_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2337\/db15-1028","volume":"65","author":"LMM Gommers","year":"2016","unstructured":"Gommers LMM, Hoenderop JGJ, Bindels RJM, de Baaij JHF. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes. 2016;65:3\u201313.","journal-title":"Diabetes."},{"key":"6954_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF00583277","volume":"403","author":"C Bailly","year":"1985","unstructured":"Bailly C, Roinel N, Amiel C. Stimulation by glucagon and PTH of Ca and Mg reabsorption in the superficial distal tubule of the rat kidney. Pflugers Arch. 1985;403:28\u201334.","journal-title":"Pflugers Arch"},{"key":"6954_CR59","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ki.1997.443","volume":"52","author":"GA Quamme","year":"1997","unstructured":"Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney Int. 1997;52:1180\u201395.","journal-title":"Kidney Int"},{"issue":"2","key":"6954_CR60","doi-asserted-by":"publisher","first-page":"e2844","DOI":"10.1002\/dmrr.2844","volume":"33","author":"Li Hao Richie Xu","year":"2016","unstructured":"Xu LHR, Maalouf NM. Effect of acute hyperinsulinemia on magnesium homeostasis in humans. Diabetes Metab Res Rev. 2017;33. https:\/\/doi.org\/10.1002\/dmrr.2844.","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"6954_CR61","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/BF00869264","volume":"29","author":"G Paolisso","year":"1986","unstructured":"Paolisso G, Sgambato S, Passariello N, Giugliano D, Scheen A, D\u2019Onofrio F, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia. 1986;29:644\u20137.","journal-title":"Diabetologia."},{"key":"6954_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","volume":"3","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6954_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.dsx.2017.08.003","volume":"12","author":"TD Filippatos","year":"2018","unstructured":"Filippatos TD, Tsimihodimos V, Liamis G, Elisaf MS. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab Syndr Clin Res Rev. 2018;12:59\u201363.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"6954_CR64","doi-asserted-by":"publisher","unstructured":"Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, et al. Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI insight. 2018;3. https:\/\/doi.org\/10.1172\/jci.insight.99123.","DOI":"10.1172\/jci.insight.99123"},{"key":"6954_CR65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jbmr.2606","volume":"31","author":"SK Murali","year":"2016","unstructured":"Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG. FGF23 regulates bone mineralization in a 1,25(OH) 2 D 3 and Klotho-independent manner. J Bone Miner Res. 2016;31:129\u201342.","journal-title":"J Bone Miner Res"},{"key":"6954_CR66","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2003","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2003;19:429\u201335.","journal-title":"J Bone Miner Res"},{"key":"6954_CR67","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","volume":"30","author":"MR Weir","year":"2014","unstructured":"Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759\u201368.","journal-title":"Curr Med Res Opin"},{"key":"6954_CR68","doi-asserted-by":"crossref","unstructured":"Kohn DF, Clifford CB. Biology and diseases of rats. Lab Anim Med. Elsevier. 2002:121\u201365.","DOI":"10.1016\/B978-012263951-7\/50007-7"},{"key":"6954_CR69","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dom.12742","volume":"18","author":"HL Tang","year":"2016","unstructured":"Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18:1199\u2013206.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"6954_CR70","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.2337\/dc19-0849","volume":"42","author":"Devin Abrahami","year":"2019","unstructured":"Abrahami D, Douros A, Yin H, Yu OHY, Azoulay L. Sodium\u2013Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. Diabetes Care. 2019; 42. https:\/\/doi.org\/10.2337\/dc19-0849.","journal-title":"Diabetes Care"},{"key":"6954_CR71","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/ndt\/gfn233","volume":"23","author":"WAKM Windt","year":"2008","unstructured":"Windt WAKM, Henning RH, Kluppel ACA, Xu Y, de Zeeuw D, van Dokkum RPE. Myocardial infarction does not further impair renal damage in 5\/6 nephrectomized rats. Nephrol Dial Transplant. 2008;23:3103\u201310.","journal-title":"Nephrol Dial Transplant"},{"key":"6954_CR72","doi-asserted-by":"publisher","first-page":"F1253","DOI":"10.1152\/ajprenal.00392.2012","volume":"303","author":"LG Bongartz","year":"2012","unstructured":"Bongartz LG, Braam B, Gaillard CA, Cramer MJ, Goldschmeding R, Verhaar MC, et al. Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Physiol. 2012;303:F1253\u201363.","journal-title":"Am J Physiol Physiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06954-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-020-06954-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06954-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:44:39Z","timestamp":1722584679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-020-06954-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["6954"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-06954-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"17 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was approved by the University of Groningen Ethical Committee on Animal Experimentation (IvD number: 16487-02-001). The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and in accordance with national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"SRY, HHWS, HvG, JLH, HJLH, LMM, SUO and BDW do not report conflicts of interest relative to this report. The UMCG employs Dr. De Boer who has received research grants and\/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Roche, Trevena and ThermoFisher GmbH. Dr. de Boer received personal fees from MandalMed Inc., Novartis and Servier.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}